LYON, France–( BUSINESS WIRE )– Regulatory News:
boxel in ( Euronext (EPA:): POXEL – FR0012432516), a clinical-stage biopharmaceutical company developing innovative therapies for serious, chronic diseases with metabolic pathophysiology, including metabolic syndrome-associated steatohepatitis (MASH) and rare metabolic disorders, today announced the availability of… Its semi-annual financial report until June 30, 2024.
The semi-annual financial report includes the following:
- Condensed consolidated financial statements for the first half of 2024, as of June 30, 2024;
- Semi-annual activity report;
- Certificate of the person responsible for the semi-annual financial report;
- The statutory auditors' limited review report on the semi-annual financial information, which includes the inability to reach a conclusion due to uncertainty surrounding going concern.
This document is available in French on the Poxel website www.poxelpharma.com in the Investor/Shareholder Information/Regulatory Documents section.
on Boxel sa (EPA:)
Boxil is Clinical stage biopharmaceutical company development Innovative treatments for chronic serious diseases with metabolic pathophysiologyincluded Metabolism-associated steatohepatitis (MASH) and rare disorders. To treat MASH, PXL065 (Deuterium stabilized R-Pioglitazone met the primary endpoint in the streamlined phase 2 trial (DESTINY-1). In rare diseases, development PXL770a first-in-class adenosine monophosphate direct activator of protein kinase (AMPK), focuses on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). TWIMIG® (Imeglimin), Poxel's first-in-class product targeting mitochondrial dysfunction, is now being marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan. Poxel is listed on Euronext Paris and is headquartered in Lyon, France, with subsidiaries in Boston, Massachusetts, and Tokyo, Japan.
For more information, please visit: www.poxelpharma.com
View source version on Businesswire.com: https://www.businesswire.com/news/home/20241222638171/en/
Investor Relations/Media
newcap
Nicola Fossiez, Aurelie Manafarire / Arthur Ruelly
Investor@poxelpharma.com
+33 1 44 71 94 94
Source: Boxil SA
